<code id='A3D3D2F776'></code><style id='A3D3D2F776'></style>
    • <acronym id='A3D3D2F776'></acronym>
      <center id='A3D3D2F776'><center id='A3D3D2F776'><tfoot id='A3D3D2F776'></tfoot></center><abbr id='A3D3D2F776'><dir id='A3D3D2F776'><tfoot id='A3D3D2F776'></tfoot><noframes id='A3D3D2F776'>

    • <optgroup id='A3D3D2F776'><strike id='A3D3D2F776'><sup id='A3D3D2F776'></sup></strike><code id='A3D3D2F776'></code></optgroup>
        1. <b id='A3D3D2F776'><label id='A3D3D2F776'><select id='A3D3D2F776'><dt id='A3D3D2F776'><span id='A3D3D2F776'></span></dt></select></label></b><u id='A3D3D2F776'></u>
          <i id='A3D3D2F776'><strike id='A3D3D2F776'><tt id='A3D3D2F776'><pre id='A3D3D2F776'></pre></tt></strike></i>

          knowledge

          knowledge

          author:fashion    Page View:11397
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          What to know about a major upcoming Wegovy heart health study
          What to know about a major upcoming Wegovy heart health study

          AdobeAtsomepointthissummer,thedrugmakerNovoNordiskwillreleaseresultsfromacloselywatchedstudythat,ifs

          read more
          At least 13 dead in Texas as scorching temps continue
          At least 13 dead in Texas as scorching temps continue

          1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

          read more

          Neutralizing antibodies against HIV shows promise in children

          BuddingHIVvirions.NIAID/NIHWhenchildrenlivingwithHIVareinjectedwithneutralizingantibodies,thetreatme